Developer docs
API playgroundTry for free, no card

Search company profiles

Neuro42

Full company profile

uuid0000qvj

Namestring
Neuro42
Legal namestring
Neuro42, Inc.
Websiteurl
neuro42.ai
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Neuro42 is a San Francisco-based medical technology company developing and commercializing a portable, low-field MRI platform combined with AI-powered image analysis and robotic intervention capabilities for neurological diagnosis and treatment. The core product is the FDA 510(k) cleared Diagnostic MRI Platform, a compact, low-field scanner intended for point-of-care neuroimaging at the bedside, in clinics, urgent care, or remote locations, with over 1,000 cumulative scans performed. The company is also developing an Interventional MRI Module that combines robotic assistance with live MRI guidance for procedures such as brain biopsies, ablations, and tumor resections, though this module is still pending regulatory clearance.

The company's business model is anchored on enterprise hardware sales of portable MRI systems to hospitals, stroke centers, urgent care, and skilled nursing facilities via a direct sales motion, supplemented by recurring service/support and potential subscription-based AI offerings, with quote-based, multi-year contracts. Neuro42 protects its platform with over 40 patents and technology rooted in Dr. Lawrence Wald's research at the Harvard/MGH Martinos Center. It serves primary customer segments of neurosurgeons, neuroradiologists, ER/stroke centers, and a secondary segment of sports organizations and athletes, with named reference accounts including Sutter Medical Center and Banner Health.

Since its founding in 2020/2021, Neuro42 has raised approximately $36.55 million in total funding across a Series A led by Zepp Health Corp., an NIH/NINDS grant, and ongoing securities offerings, while securing surgical robotics pioneer Fred Moll as a strategic advisor. The company operates with 11-50 employees and is led by President & CEO Amit Vohra, Chief Strategy Officer Abhita Batra, and Chief Development Officer Nikhil Sadhwani, with PhD-level SVPs heading MRI and robotics development.

Short descriptiontext

Neuro42 is a San Francisco-based medical technology company that develops and sells FDA 510(k) cleared portable, low-field MRI systems with AI-powered image analysis and robotic intervention capabilities, serving neurosurgeons, stroke centers, and other healthcare facilities for point-of-care brain imaging.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
portable MRI systems, neuroimaging diagnostics, image-guided neurosurgery, point-of-care imaging, MRI robotics platform
Industry3 codes
PRIMARYHLAHABAC
Magnetic Resonance Imaging (MRI) Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHDAAAEAH
Medical Imaging AI
SECONDARYHLAKAIAL
Neuro-oncology
NAICS code3 codes
  • Surgical and Medical Instrument Manufacturing339112
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing33451
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing3345
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Medical Imaging Equipment
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Portable MRI Hardware Sales
TypeHardware Sales
Description

Sale of portable MRI systems to healthcare facilities including hospitals, stroke centers, urgent care, and skilled nursing facilities.

neuro42.ai
2Service and Support
TypeSubscription Recurring
Description

Ongoing maintenance, support, and potentially subscription-based AI/software services for the MRI platform.

neuro42.ai
3Interventional Robotics Module
TypeHardware Sales
Description

Future revenue stream from robotic intervention modules pending regulatory clearance.

neuro42.ai
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations
Pricing details1 tier
1Enterprise medical imaging system - pricing available upon request
ModelOtherBilling cadenceMulti-year contract
Notes

Quote-based / Not publicly disclosed. System includes portable MRI hardware, software platform, and optional robotic module.

neuro42.ai
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Neuro42 develops and commercializes a portable, FDA 510(k) cleared low-field MRI scanner for point-of-care neuroimaging, combined with AI-powered image analysis and a robotic intervention module (pending regulatory clearance) for MRI-guided neurosurgical procedures such as brain biopsies, ablations, and tumor resections. The platform is designed to bring imaging to the bedside or clinic, reducing patient transport and accelerating diagnosis for stroke, brain lesions, and other neurological conditions.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Reduced patient transportation - system brings imaging to patient rather than requiring transport
+2 more records
Product overview1 text field

Neuro42 offers a portable MRI platform combining diagnostic imaging with AI-powered analysis and robotic-guided surgical intervention capabilities. The core product is the FDA 510(k) cleared Diagnostic MRI Platform, a portable low-field scanner for point-of-care neuroimaging. An add-on Interventional MRI Module (in development) enables MRI-guided robotic procedures. The company also operates a Sports Brain Health Partnership Program providing brain scanning services for athletes.

Product and service3 records
1Diagnostic MRI Platform
CategoryMedical Imaging Equipment
Description

FDA 510(k) cleared portable, low-field MRI scanner for point-of-care neuroimaging, enabling rapid bedside diagnosis of stroke and brain conditions at clinics, urgent care, and remote locations. Sold to hospitals, stroke centers, urgent care, and skilled nursing facilities.

2Interventional MRI Module
CategoryMedical Robotics / Surgical Intervention
Description

MRI-guided robotic intervention system designed for neurosurgical procedures including brain biopsies, ablations, and tumor resections under live MRI guidance. Designed for neurosurgeons at hospitals and neurosurgical centers.

3Sports Brain Health Partnership Program
CategorySports Medicine Services
Description

Partnership program providing pre-game screening, baseline and post-game brain scans for athletes in high-impact sports including boxing, football, wrestling, and soccer. Targeted at sports leagues, trainers, and athletes.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
1Lawrence Wald (Harvard/MGH)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Technology developed by Dr. Lawrence Wald's group at the Athinoula A. Martinos Center for Biomedical Imaging serves as the foundation for neuro42's portable MRI technology. Dr. Wald is a Professor of Radiology at Harvard and Biophysicist at MGH.

neuro42.ai
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partnership with National Brain Tumor Society including participation in Miles for Milestones challenge that raised $950,000 for brain tumor research.

3Cris Cyborg
Strategic tierMinorTypeGTM or Marketing Partner
Description

Partnership with UFC fighter Cris Cyborg for sports brain health initiatives and athlete brain monitoring programs.

neuro42.ai
Strategic tierMinorTypeGTM or Marketing Partner
Description

Collaboration with Barwis Methods athlete performance training organization for brain health and performance optimization programs.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Hyperfine develops the Swoop portable low-field MRI system for point-of-care brain imaging, the most direct head-to-head competitor to Neuro42's portable MRI platform with overlapping target customers (hospitals, ICUs, ERs) and similar FDA pathway.

TypeDirect peer
Description

Promaxo builds office-based MRI systems for prostate and urological applications using a portable, AI-driven platform with similar miniaturization philosophy and clinical workflow positioning, and shares leadership overlap with Neuro42 (Promaxo developed by Abhita Batra's prior work).

TypeEmerging player
Description

Synaptive Medical combines surgical robotics, intraoperative imaging, and AI for neurosurgery — overlapping with Neuro42's planned interventional MRI + robotics platform and competing in the same neurosurgical operating room workflow.

TypeDirect peer
Description

IMRIS provides intraoperative MRI systems that move into the OR for neurosurgical guidance, a directly comparable clinical use case (image-guided neurosurgery) to Neuro42's interventional module roadmap.

TypeBroad incumbent
Description

GE HealthCare is one of the largest MRI manufacturers globally with broad hospital installed base and full radiology portfolio, representing the dominant incumbent that Neuro42 must displace or partner with for budget share.

TypeBroad incumbent
Description

Siemens Healthineers offers a comprehensive MRI product line (including 0.55T low-field systems) plus AI image analysis — overlapping directly with Neuro42's diagnostic imaging value proposition as a scaled competitor.

TypeBroad incumbent
Description

Philips is a major MRI and image-guided therapy vendor with strong neurology and stroke care presence, the broadest incumbent competitive threat across both diagnostic and interventional use cases.

TypeBroad incumbent
Description

Canon Medical manufactures MRI systems across field strengths and is an established hospital vendor in radiology, representing another large incumbent competing for imaging capital budgets.

TypeEmerging player
Description

Insightec develops MR-guided focused ultrasound for non-invasive neurosurgery, overlapping with Neuro42's image-guided interventional ambition in the same neurosurgical patient population with a different (non-robotic) modality.

TypeEmerging player
Description

Profound Medical offers MR-guided transurethral ultrasound and other image-guided interventional platforms, sharing the playbook of combining imaging with therapeutic intervention in a single device workflow.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Neuro42

Medical Imaging Equipmentneuro42.ai

Neuro42 is a San Francisco-based medical technology company that develops and sells FDA 510(k) cleared portable, low-field MRI systems with AI-powered image analysis and robotic intervention capabilities, serving neurosurgeons, stroke centers, and other healthcare facilities for point-of-care brain imaging.

What Neuro42 does

Neuro42 is a San Francisco-based medical technology company developing and commercializing a portable, low-field MRI platform combined with AI-powered image analysis and robotic intervention capabilities for neurological diagnosis and treatment. The core product is the FDA 510(k) cleared Diagnostic MRI Platform, a compact, low-field scanner intended for point-of-care neuroimaging at the bedside, in clinics, urgent care, or remote locations, with over 1,000 cumulative scans performed. The company is also developing an Interventional MRI Module that combines robotic assistance with live MRI guidance for procedures such as brain biopsies, ablations, and tumor resections, though this module is still pending regulatory clearance.

The company's business model is anchored on enterprise hardware sales of portable MRI systems to hospitals, stroke centers, urgent care, and skilled nursing facilities via a direct sales motion, supplemented by recurring service/support and potential subscription-based AI offerings, with quote-based, multi-year contracts. Neuro42 protects its platform with over 40 patents and technology rooted in Dr. Lawrence Wald's research at the Harvard/MGH Martinos Center. It serves primary customer segments of neurosurgeons, neuroradiologists, ER/stroke centers, and a secondary segment of sports organizations and athletes, with named reference accounts including Sutter Medical Center and Banner Health.

Since its founding in 2020/2021, Neuro42 has raised approximately $36.55 million in total funding across a Series A led by Zepp Health Corp., an NIH/NINDS grant, and ongoing securities offerings, while securing surgical robotics pioneer Fred Moll as a strategic advisor. The company operates with 11-50 employees and is led by President & CEO Amit Vohra, Chief Strategy Officer Abhita Batra, and Chief Development Officer Nikhil Sadhwani, with PhD-level SVPs heading MRI and robotics development.

Neuro42 firmographics

Firmographics
Name
Neuro42
Legal name
Neuro42, Inc.
Website
https://neuro42.ai
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Short description
Neuro42 is a San Francisco-based medical technology company that develops and sells FDA 510(k) cleared portable, low-field MRI systems with AI-powered image analysis and robotic intervention capabilities, serving neurosurgeons, stroke centers, and other healthcare facilities for point-of-care brain imaging.
Ownership category
akta.pro rank

Neuro42 industry classification

Industry
Product category
Medical Imaging Equipment
NAICS
Surgical and Medical Instrument Manufacturing (339112), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)
SIC
Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHABAC
Magnetic Resonance Imaging (MRI) Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHDAAAEAH
Medical Imaging AI
SECONDARYHLAKAIAL
Neuro-oncology

Keywords

  • Portable MRI systems
  • Neuroimaging diagnostics
  • Image-guided neurosurgery
  • Point-of-care imaging
  • MRI robotics platform

Where Neuro42 is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Neuro42 business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations

Revenue model

  1. Portable MRI Hardware Sales: Sale of portable MRI systems to healthcare facilities including hospitals, stroke centers, urgent care, and skilled nursing facilities.
  2. Service and Support: Ongoing maintenance, support, and potentially subscription-based AI/software services for the MRI platform.
  3. Interventional Robotics Module: Future revenue stream from robotic intervention modules pending regulatory clearance.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractEnterprise medical imaging system - pricing available upon request

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Neuro42 product offering

Product offering

Core offering

Neuro42 develops and commercializes a portable, FDA 510(k) cleared low-field MRI scanner for point-of-care neuroimaging, combined with AI-powered image analysis and a robotic intervention module (pending regulatory clearance) for MRI-guided neurosurgical procedures such as brain biopsies, ablations, and tumor resections. The platform is designed to bring imaging to the bedside or clinic, reducing patient transport and accelerating diagnosis for stroke, brain lesions, and other neurological conditions.

Product overview

Neuro42 offers a portable MRI platform combining diagnostic imaging with AI-powered analysis and robotic-guided surgical intervention capabilities. The core product is the FDA 510(k) cleared Diagnostic MRI Platform, a portable low-field scanner for point-of-care neuroimaging. An add-on Interventional MRI Module (in development) enables MRI-guided robotic procedures. The company also operates a Sports Brain Health Partnership Program providing brain scanning services for athletes.

Differentiator

Problem solved

Functional benefit

Products and services

  • Diagnostic MRI Platform FDA 510(k) cleared portable, low-field MRI scanner for point-of-care neuroimaging, enabling rapid bedside diagnosis of stroke and brain conditions at clinics, urgent care, and remote locations. Sold to hospitals, stroke centers, urgent care, and skilled nursing facilities.
  • Interventional MRI Module MRI-guided robotic intervention system designed for neurosurgical procedures including brain biopsies, ablations, and tumor resections under live MRI guidance. Designed for neurosurgeons at hospitals and neurosurgical centers.
  • Sports Brain Health Partnership Program Partnership program providing pre-game screening, baseline and post-game brain scans for athletes in high-impact sports including boxing, football, wrestling, and soccer. Targeted at sports leagues, trainers, and athletes.

Quantifiable outcome

  • Reduced patient transportation - system brings imaging to patient rather than requiring transport
  • +2 more outcomes

Companies that use Neuro42

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Neuro42 technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature4 records

Neuro42 partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • Lawrence Wald (Harvard/MGH)coreStrategic or Co-development PartnerTechnology developed by Dr. Lawrence Wald's group at the Athinoula A. Martinos Center for Biomedical Imaging serves as the foundation for neuro42's portable MRI technology. Dr. Wald is a Professor of Radiology at Harvard and Biophysicist at MGH.
  • National Brain Tumor SocietyminorStrategic or Co-development PartnerPartnership with National Brain Tumor Society including participation in Miles for Milestones challenge that raised $950,000 for brain tumor research.
  • Cris CyborgminorGTM or Marketing PartnerPartnership with UFC fighter Cris Cyborg for sports brain health initiatives and athlete brain monitoring programs.
  • Barwis MethodsminorGTM or Marketing PartnerCollaboration with Barwis Methods athlete performance training organization for brain health and performance optimization programs.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Neuro42 competitors and assessment

Company assessment

Direct peers

  • Hyperfine: Hyperfine develops the Swoop portable low-field MRI system for point-of-care brain imaging, the most direct head-to-head competitor to Neuro42's portable MRI platform with overlapping target customers (hospitals, ICUs, ERs) and similar FDA pathway.
  • Promaxo: Promaxo builds office-based MRI systems for prostate and urological applications using a portable, AI-driven platform with similar miniaturization philosophy and clinical workflow positioning, and shares leadership overlap with Neuro42 (Promaxo developed by Abhita Batra's prior work).
  • IMRIS: IMRIS provides intraoperative MRI systems that move into the OR for neurosurgical guidance, a directly comparable clinical use case (image-guided neurosurgery) to Neuro42's interventional module roadmap.

Emerging players

  • Synaptive Medical: Synaptive Medical combines surgical robotics, intraoperative imaging, and AI for neurosurgery — overlapping with Neuro42's planned interventional MRI + robotics platform and competing in the same neurosurgical operating room workflow.
  • Insightec: Insightec develops MR-guided focused ultrasound for non-invasive neurosurgery, overlapping with Neuro42's image-guided interventional ambition in the same neurosurgical patient population with a different (non-robotic) modality.
  • Profound Medical: Profound Medical offers MR-guided transurethral ultrasound and other image-guided interventional platforms, sharing the playbook of combining imaging with therapeutic intervention in a single device workflow.

Broad incumbents

  • GE HealthCare: GE HealthCare is one of the largest MRI manufacturers globally with broad hospital installed base and full radiology portfolio, representing the dominant incumbent that Neuro42 must displace or partner with for budget share.
  • Siemens Healthineers: Siemens Healthineers offers a comprehensive MRI product line (including 0.55T low-field systems) plus AI image analysis — overlapping directly with Neuro42's diagnostic imaging value proposition as a scaled competitor.
  • Philips Healthcare: Philips is a major MRI and image-guided therapy vendor with strong neurology and stroke care presence, the broadest incumbent competitive threat across both diagnostic and interventional use cases.
  • Canon Medical Systems: Canon Medical manufactures MRI systems across field strengths and is an established hospital vendor in radiology, representing another large incumbent competing for imaging capital budgets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Neuro42 social profiles

Digital presence

Neuro42 compliance and trust

Trust signal

Compliance1 record

Neuro42 financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Neuro42 leadership team

Management profile

Number of profiles

Profiles5 records

Neuro42 funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Neuro42 M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Neuro42

What does Neuro42 do?

Neuro42 develops and commercializes a portable, FDA 510(k) cleared low-field MRI scanner for point-of-care neuroimaging, combined with AI-powered image analysis and a robotic intervention module (pending regulatory clearance) for MRI-guided neurosurgical procedures such as brain biopsies, ablations, and tumor resections. The platform is designed to bring imaging to the bedside or clinic, reducing patient transport and accelerating diagnosis for stroke, brain lesions, and other neurological conditions.

Is Neuro42 a public or private company?

Neuro42 is a private company. It is classified as venture growth investor backed and is currently operating.

When was Neuro42 founded?

Neuro42 was founded in 2021. It employs 11 to 50 people.

Where is Neuro42 based?

Neuro42 is headquartered in San Francisco, United States, in the North America region.

How does Neuro42 make money?

Three revenue lines are on record. Portable MRI Hardware Sales are the primary driver. The others are service and Support and interventional Robotics Module.

Who are Neuro42's main competitors?

Direct peers on record are Hyperfine, Promaxo and IMRIS. Emerging players are Synaptive Medical, Insightec and Profound Medical. Broad incumbents are GE HealthCare, Siemens Healthineers, Philips Healthcare and Canon Medical Systems.

Does Neuro42 have an API?

No public API is recorded for Neuro42.

What industry is Neuro42 in?

Neuro42's product category is Medical Imaging Equipment. Its primary akta.pro industry code is HLAHABAC, Magnetic Resonance Imaging (MRI) Systems, with a secondary code of HDAAAEAH, Medical Imaging AI. Its NAICS code is 339112 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
SecSEC FORM DNeuro42, Inc. filed a Form D with the SEC for an exempt securities offering under Rule 506(b), disclosing a total offering amount of approximately $36.5 million. The company has already sold roughly $15.6 million worth of equity securities to 85 investors, with about $11.6 million derived from the conversion of outstanding notes.FinSMEsneuro42 Receives Investment from Zynext Venturesneuro42, a developer of portable MRI systems based in San Francisco, received an undisclosed investment from Zynext Ventures. The funds will be used to accelerate neuro42's innovation in providing advanced imaging and treatment solutions for patients. The company has developed portable MRI and robotic intervention technology, with plans to seek regulatory clearance for its interventional module.Googleneuro42 Receives Investment from Zynext VenturesSan Francisco-based neuro42 received an undisclosed investment from Zynext Ventures to accelerate the development of its portable MRI systems and robotic intervention technology. The company, led by CEO Dr. Amit Vohra, has already secured FDA 510(K) clearance for its diagnostic platform and is currently seeking regulatory approval for its interventional module.EntrepreneurPerceptyne, ellementry, and neuro42 Raise Early-Stage FundingD2C homeware brand ellementry secured funding led by She Capital to accelerate expansion and product offerings, while medical technology company neuro42 received investment from Karna D Shinde following USFDA clearance for its portable MRI. Additionally, deep-tech robotics firm Perceptyne raised a pre-seed round led by Venture Catalysts to advance industrial humanoid robot development in the EMS and automotive sectors.GlobeNewswireneuro42 Receives Direct Investment and Appoints Surgical Robotics Industry Pioneer Fred Moll as Strategic Advisorneuro42, Inc. announced that it has received a direct investment from Dr. Fred Moll and appointed him as a strategic advisor. Dr. Moll, a leading figure in surgical robotics with over 40 years of experience, aims to contribute significantly to neuro42's technology platform as it seeks to change surgical standards in neurosurgery.GlobeNewswireneuro42 Receives $5 Million NIH Grant for Research on Portable Intraoperative MRI for Neurosurgeryneuro42, Inc. has received a $5 million grant from the National Institute of Neurological Disorders and Stroke (NINDS) to research portable intraoperative MRI systems for neurosurgery. The funding aims to advance MRI-compatible robotic technologies to guide interventional procedures such as brain biopsies and tumor resections. This initiative supports neuro42's goal of optimizing patient outcomes in treating conditions like brain tumors, epilepsy, and Parkinson’s disease.AiThorityZepp Health Invests $2.4M to Lead neuro42’s Series A RoundZepp Health invested $2.4 million to lead a $6.5 million Series A round for neuro42, which develops MRI and robotics technology for diagnosing brain injury and treating neurological diseases under live imaging. The company holds an exclusive worldwide license of low-field MR imaging technology from Dr. Lawrence Wald's lab at the Martinos Center.BioSpaceIMIDomics, IgGenix and neuro42 Close Series A Rounds Worth MillionsThree companies announced the closing of Series A financing: IMIDomics raised $16.5 million led by DNS Capital, IgGenix raised $25 million led by Khosla Ventures and Mattias Westman, and neuro42 raised $6.5 million led by Zepp Health. IMIDomics targets immune-mediated diseases including lupus and Crohn's, IgGenix focuses on allergies, and neuro42 advances MRI and robotics for brain injury diagnosis.PR NewswireZepp Health Invests $2.4M to Lead neuro42's Series A RoundZepp Health Corp. is investing $2.4 million to lead a $6.5 million Series A funding round for neuro42, Inc., aimed at developing MRI and robotics technology for diagnosing and treating neurological diseases. This investment marks Zepp Health's third venture into medical imaging technologies, bolstering its commitment to integrating health and technology. The partnership is expected to enhance healthcare delivery by providing a competitive edge in portable MRI technology.